Plasma interferon-γ-inducible protein 10 (IP-10) levels correlate with disease severity and paradoxical reactions in extrapulmonary tuberculosis
Open Access
- 2 November 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Infection
- Vol. 49 (3), 437-445
- https://doi.org/10.1007/s15010-020-01541-1
Abstract
Background With 1.5 million deaths worldwide in 2018, tuberculosis (TB) remains a major global public health problem. While pulmonary TB (PTB) is the most common manifestation, the proportion of extrapulmonary TB (EPTB) is increasing in low-burden countries. EPTB is a heterogeneous disease entity posing diagnostic and management challenges due to the lack of reliable biomarkers. In this study, we prospectively evaluated clinical data and treatment response which were correlated with different biomarkers. Methods The study was conducted at the University Hospital of Cologne. 20 patients with EPTB were enrolled. We analyzed plasma interferon-γ-inducible protein 10 (IP-10) levels in plasma by ELISA for up to 12 months of treatment. In addition, the QuantiFERON®-TB Gold Plus (QFT® Plus) test was performed during the course of treatment. Clinical data were assessed prospectively and correlated with QFT® Plus and IP-10 levels. Results Plasma IP-10 levels were found to be significantly increased (p < 0.001) in patients with extensive disease compared to patients with limited disease (cervical lymph node TB) or healthy controls. In patients with clinically confirmed paradoxical reaction (PR), a further increase of IP-10 was noted. IFN-γ measured by the QFT® Plus test did not decrease significantly during the course of treatment. Of note, in four EPTB patients (20%) without radiographic pulmonary involvement, sputum culture was positive for Mycobacterium tuberculosis. Conclusion Our data demonstrate that IP-10 may be a valuable biomarker for estimation of disease severity in EPTB and monitoring of the disease course in extensive forms. However, IP-10 may be less suitable for diagnosis and monitoring of EPTB patients with limited disease. The QFT® Plus test does not appear to be a suitable marker for therapy monitoring. Sputum should be examined in EPTB patients even in case of normal diagnostic imaging of the chest.Keywords
Funding Information
- Deutsches Zentrum für Infektionsforschung (TI 07.001_SUAREZ_00, TTU 02.806 and 02.905)
- Deutsche Forschungsgemeinschaft (DFG RY159)
This publication has 35 references indexed in Scilit:
- Plasma cytokines and chemokines differentiate between active disease and non-active tuberculosis infectionJournal of Infection, 2013
- Gamma Interferon Release Assay for Monitoring of Treatment Response for Active Tuberculosis: an Explosion in the Spaghetti FactoryJournal of Clinical Microbiology, 2013
- Paradoxical reactions during treatment of tuberculosis with extrapulmonary manifestations in HIV-negative patientsInfection, 2012
- Predictors of pulmonary involvement in patients with extra-pulmonary tuberculosisJournal of Family and Community Medicine, 2012
- HIV & immune reconstitution inflammatory syndrome (IRIS)Indian Journal of Medical Research, 2011
- Hypercytokinaemia accompanies HIV-tuberculosis immune reconstitution inflammatory syndromeEuropean Respiratory Journal, 2010
- Sputum monitoring during tuberculosis treatment for predicting outcome: systematic review and meta-analysisThe Lancet Infectious Diseases, 2010
- Increase in extrapulmonary tuberculosis in England and Wales 1999-2006Thorax, 2009
- Determinants of Immune Reconstitution Inflammatory Syndrome in HIV Type 1–Infected Patients with Tuberculosis after Initiation of Antiretroviral TherapyClinical Infectious Diseases, 2004
- Paradoxical reactions during tuberculosis treatment in patients with and without HIV co-infectionThorax, 2004